Trulieve Cannabis Corp., a leading U.S. medical cannabis company, has received approval to list its subordinate voting shares on the New York Stock Exchange (NYSE). The shares are expected to begin trading under the ticker symbol "TRLV" at market open on Wednesday, June 10, 2026.
Historic Milestone for Cannabis Industry
Kim Rivers, Founder and CEO of Trulieve, stated, "As the first U.S. cannabis company to list on a major U.S. exchange, we are excited for the opportunity to expand our shareholder base, increase liquidity, and raise awareness for the benefits of medical marijuana. Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone."
Rescheduling and Corporate Restructuring
In April 2026, Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III, following President Trump's Executive Order in December 2025. This rescheduling created a pathway for DEA registration for state-licensed medical marijuana businesses. Subsequently, Trulieve completed a corporate restructuring and third-party investment, deconsolidating operations in markets serving both medical and adult-use customers. The company's remaining consolidated operations now consist solely of state-licensed medical marijuana facilities, including 206 dispensaries supported by 3.5 million square feet of production capacity registered with the DEA.
Future Expansion and Trading Details
Trulieve plans to expand in Georgia and Texas, leveraging robust cash generation. The company expects its shares to continue trading on the Canadian Securities Exchange (CSE) under "TRUL" and on the OTCQX under "TCNNF" until market close on June 9, 2026. Current shareholders need not take any action prior to the NYSE listing.
Forward-Looking Statements
This news release contains forward-looking statements regarding the NYSE listing, shareholder base expansion, liquidity enhancement, and expansion in Georgia and Texas. These statements are based on current expectations and assumptions, subject to risks and uncertainties detailed in the company's filings with the SEC and on SEDAR+. Trulieve assumes no obligation to update these statements.
